Time for international action on treating testosterone deficiency syndrome

Figures & data

Table I.  Numbers of men in millions at risk of TDS in various age categories, estimates being made around 2006

Region	Age 50–64	Age 65–79	Age 80+
Whole EU	42.53	29.61	9.63
UK	4.99	3.26	1.23
Ireland	0.33	0.17	0.04
Spain	3.44	3.25	1.23
Italy	5.23	4.17	1.46
France	5.32	3.45	1.36
Germany	6.48	5.21	1.58
America	25.14	11.76	3.82
Russia	10.60	4.90	1.50
Australia	1.72	0.94	0.27

Table II.  Number of men over 50, and those expected to be androgen deficient on the basis either of symptoms alone (20%), or with symptoms and low TT and CFT (5%), compared with total number being treated in each region. Estimates are made for around 2006

Region	Men aged >50 (Millions)	TDS symptoms (Millions)	Total number treated	Symptoms treated (%)	Sympt. +biochem. (Millions)	Symptoms +biochem treated (%)
Whole EU	81.77	16.35	113,000	0.69	4.09	2.76
UK	9.48	1.90	19,000	1.00	0.47	4.00
Ireland	0.54	0.11	1,000	1.10	0.27	4.40
Spain	7.92	1.58	12,000	0.76	0.40	3.04
Italy	10.86	2.17	11,000	0.51	0.54	2.03
France	10.13	2.03	10,000	0.49	0.51	1.97
Germany	13.27	2.65	50,000	1.89	0.66	7.55
America	40.72	8.14	648,000	7.96	2.04	31.84
Russia	17.00	3.40	18,400	0.54	0.85	2.16
Australia	2.93	0.59	9,100	1.54	0.15	6.17

Table III.  Absorption, theoretical and practical advantages, together with costs, of each preparation and their application at NHS prices (£), giving a monthly total treatment cost, excluding medical costs of diagnosis and monitoring treatment. Theoretical and practical aspects of each treatment are rated from *poor, **moderate, ***good, to ****excellent

Testosterone preparation	% Abs.	Theory	Practice	Cost	Appl.	Total
Testosterone pellet implant	100	*	**	14	50	64
Injected T-esters (Sustenon)	100	*	*	5	20	25
Injected T-undecanoate (Nebido)	100	**	***	25	5	30
Oral T-undecanoate (Testocaps)	10	**	**	36	0	36
T-Gel (Testogel, Tostran, Testim)	15	***	***	33	0	33
Scrotal T (Andromen, Tostran)	70	****	****	13	0	13